Enterprise Value
260.2M
Cash
56.95M
Avg Qtr Burn
-17.27M
Short % of Float
2.80%
Insider Ownership
1.28%
Institutional Own.
29.15%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Auryxia (ferric citrate) Details Chronic kidney disease, Anemia, Kidney disease, Hyperphosphatemia | Approved Quarterly sales | |
Vafseo™ (Vadadustat) Details Chronic kidney disease, Anemia, Kidney disease | NDA Resubmission |